Saudi Central Bank Acquires 4,795 Shares of Illumina, Inc. $ILMN

Saudi Central Bank lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 85.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,435 shares of the life sciences company’s stock after acquiring an additional 4,795 shares during the period. Saudi Central Bank’s holdings in Illumina were worth $1,835,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Elyxium Wealth LLC acquired a new stake in Illumina in the 4th quarter worth $25,000. Fiduciary Financial Advisors bought a new position in shares of Illumina during the 2nd quarter worth about $26,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina during the second quarter valued at about $32,000. Quarry LP acquired a new position in shares of Illumina during the third quarter valued at about $32,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Illumina in the fourth quarter valued at about $33,000. Institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In other Illumina news, Director Keith Meister sold 119,501 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the sale, the director directly owned 770,350 shares in the company, valued at $168,244,440. This represents a 13.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,062,465 shares of company stock worth $436,589,802 over the last quarter. Company insiders own 2.90% of the company’s stock.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: S&P 500 inclusion should support demand. Illumina will join the S&P 500 before the market opens on September 21, moving up from the S&P MidCap 400. The change is expected to generate buying from index-tracking funds and increase the company’s visibility among institutional investors. Illumina and Everpure to Join S&P 500 in September Rebalancing
• Positive Sentiment: Analyst sentiment has improved. Zacks upgraded Illumina to Rank #2, or “Buy,” citing greater optimism about its earnings outlook. The upgrade could provide additional short-term momentum. Illumina Upgraded to Buy
• Positive Sentiment: Business quality remains a bullish theme. Commentary highlights Illumina’s leadership in gene sequencing and the expanding use of genomics in diagnostics and precision medicine. Investors are weighing whether continued operational strength can justify the stock’s recent advance. ILMN Stock Keeps Climbing

Illumina Stock Performance

NASDAQ:ILMN opened at $211.06 on Wednesday. The firm has a market capitalization of $31.87 billion, a PE ratio of 39.38, a price-to-earnings-growth ratio of 3.09 and a beta of 1.46. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $231.81. The firm has a 50-day moving average price of $199.86 and a 200 day moving average price of $160.68.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the business earned $1.19 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent research reports. Guggenheim lifted their target price on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Citigroup upped their price target on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a report on Monday, August 3rd. Stifel Nicolaus lifted their price objective on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a research report on Wednesday, August 5th. Finally, Royal Bank Of Canada upped their target price on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $191.31.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.